SCHEMBL5048916

SCHEMBL5048916

Clc1ccc(CNCC2CCCCC2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.50
TRPA1 O75762 1/20 0.47
OXTR P30559 1/20 0.47
AVPR1A P37288 1/20 0.47
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
ALDH1A1 P00352 3/20 0.45
KDM1A O60341 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
PRMT5 O14744 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047960 0.98 TRPA1 (0.48) HDAC6TRPA1OXTRAVPR1AKDM4E
SCHEMBL22499093 0.95 OXTR (0.48) HDAC6TRPA1OXTRAVPR1AKDM4E
SCHEMBL30811780 0.95 OXTR (0.48) HDAC6TRPA1OXTRAVPR1AKDM4E
SCHEMBL2584901 0.78 POLB (0.58) KDM4EGAAMAPTL3MBTL1HDAC1
SCHEMBL9279836 0.78 GAA (0.63) OXTRAVPR1AKDM4EGAAMAPT
SCHEMBL4736629 0.76 POLB (0.60) KDM4EGAAMAPTL3MBTL1HDAC1
SCHEMBL1565304 0.75 PRMT5 (0.73) HDAC6L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL1565525 0.74 CYP1A2 (0.61) HDAC6KDM4EGAAALDH1A1CXCR4
SCHEMBL3861590 0.74 HDAC6 (0.62) HDAC6HDAC3HDAC4HDAC1HDAC8
SCHEMBL13927593 0.73 KCNH2 (0.44) HDAC6HDAC3HDAC4HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345038-B2 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives PFIZER, INC (US) 2008-03-18 US disclosed
EP-1608648-A1 PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES Pfizer Products Inc. (US) 2005-12-28 EP disclosed
US-20050026922-A1 For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine PFIZER INC 2005-02-03 US disclosed
WO-2004081007-A1 PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026922-A1 For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine GRM7, GRIN2C, HTR7 HDAC6 391/4885TRPA1 4141/4885OXTR 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.